Research Information System
PHARMACOLOGY, vol.80, no.4, pp.227-238, 2007 (SCI-Expanded)
The contribution of beta-adrenoceptor subtypes to the catecholamine-mediated relaxations in gastric fundus from control and streptozotocin ( STZ)-induced diabetic rats were investigated. Isolated organ bath studies and molecular techniques were used to characterize the beta-adrenoceptor subtypes mediating relaxation of rat gastric fundus. Isoprenaline-mediated relaxation was not significantly changed by nadolol (beta(1)-/beta(2)-adrenoceptor antagonist; 1 mu mol/l) but only shifted to the right by SR59230A ( 3-(2-ethylphenoxy)-1[[(1S)-1,2,3,4-tetrahydronaphth-1- yl] amino]-(2S)-2-propanol oxalate salt, 0.1-1 mu mol/ l), a selective beta(3)-adrenoceptor antagonist, in a competitive manner. Relaxant responses to noradrenaline were antagonized in a concentration-dependent manner by SR59230A ( 0.1-1 mu mol/ l), but not by metoprolol ( selective beta(1)-adrenoceptor antagonist; 0.1-1 mu mol/ l) and ICI-118551 ( 1-[2,3-(dihydro-7-methyl-1Hinden-4- yl) oxy]-3-[(1-methylethyl)amino]-2-butanol hydrochloride, selective beta(2)-adrenoceptor antagonist; 0.1-1 mu mol/l). SR59230A ( 1 mu mol/ l) also caused a significant rightward shift in fenoterol-induced relaxation while ICI- 118551 ( 1 mu mol/ l) did not have any effect. Selective beta(3)-adrenoceptor agonist, BRL37344 ([ 4-[2-[[2-(3-chlorophenyl)-2-hydroxyethyl] amin o] propyl] phenoxy] acetic acid), caused biphasic relaxation which was not affected by nadolol ( 1 mu mol/ l). SR59230A ( 1 mu mol/ l) abolished only the first phase of BRL37344 response. beta(1)-, beta(2)- and beta(3)-adrenoceptor mRNA expressions have been detected in a similar intensity in gastric fundus from control rats. Experimental diabetes caused a significant decrease in E-max and pD(2) values of isoprenaline and noradrenaline. Diabetes also reduced E-max but not pD(2) value of the first component of BRL37344-induced relaxation response. The band intensity of mRNA transcript of beta(3)-adrenoceptor was reduced in diabetics while no alteration has been found for beta(1)- and beta(2)-adrenoceptor mRNA transcripts between groups. These results show that functional beta-adrenoceptor subtype involved in catecholamine-mediated relaxations is beta(3)-adrenoceptor, and its function and mRNA expression are decreased in diabetes. Copyright (c) 2007 S. Karger AG, Basel.